Literature DB >> 18451067

Four-fraction radiation therapy for macroscopic soft tissue sarcomas in 16 dogs.

Jessica Lawrence1, Lisa Forrest, William Adams, David Vail, Douglas Thamm.   

Abstract

A retrospective study of 16 dogs with macroscopic soft tissue sarcomas was performed to evaluate response to a four-fraction radiotherapy protocol (prescribed dose of 32 Gy). Radiation was well tolerated with minimal side effects. The overall response rate was 50%, with seven partial responses and one complete response. The median time to progression was 155 days, and the median survival time was 309 days. Coarsely fractionated radiation therapy may be a reasonable palliative option for dogs with unresectable soft tissue sarcomas, although the response is relatively short-lived.

Entities:  

Mesh:

Year:  2008        PMID: 18451067     DOI: 10.5326/0440100

Source DB:  PubMed          Journal:  J Am Anim Hosp Assoc        ISSN: 0587-2871            Impact factor:   1.023


  4 in total

1.  Radiation therapy for palliation of sarcoma metastases: a unique and uniform hypofractionation experience.

Authors:  Viacheslav Soyfer; Benjamin W Corn; Yehuda Kollender; Haim Tempelhoff; Isaac Meller; Ofer Merimsky
Journal:  Sarcoma       Date:  2010-03-08

Review 2.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

3.  Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model.

Authors:  Michael W Nolan; Tracy L Gieger; Alexander A Karakashian; Mariana N Nikolova-Karakashian; Lysa P Posner; Donald M Roback; Judith N Rivera; Sha Chang
Journal:  Technol Cancer Res Treat       Date:  2017-02-07

4.  The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study.

Authors:  Annika N Haagsman; Astrid C S Witkamp; Bart E Sjollema; Marja J L Kik; Jolle Kirpensteijn
Journal:  BMC Vet Res       Date:  2013-08-08       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.